Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.750 +0.020 (+0.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Where Will Editas Medicine Be in 1 Year? ↗

November 20, 2022

The company could continue lagging the market for a while.

Via The Motley Fool

Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment ↗

November 18, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022 ↗

November 18, 2022

Upgrades

Via Benzinga

Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne ↗

November 18, 2022

Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell...

Via Benzinga

Why Editas Medicine's Shares Are Falling Thursday ↗

November 17, 2022

The company shelved a clinical trial for one of its lead therapies.

Via The Motley Fool

Editas Medicine: Q3 Earnings Insights ↗

November 02, 2022

Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Intuit To $490? Here Are 5 Other Price Target Changes For Friday ↗

November 18, 2022

Barclays cut Intuit Inc. (NASDAQ: INTU) price target from $502 to $490. . Barclays analyst Raimo Lenschow maintained an Overweight rating on the stock. Intuit shares fell 3% to close at $381.88 on...

Via Benzinga

Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50% ↗

November 18, 2022

Telsey Advisory Group boosted the price target on The Gap, Inc. (NYSE: GPS) from $10 to $15. Gap shares rose 5.6% to close at $12.71 on Thursday.

Via Benzinga

Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings ↗

November 17, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday.

Via Benzinga

Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session ↗

November 17, 2022

Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67...

Via Benzinga

Editas Medicine's Return On Capital Employed Insights ↗

August 10, 2022

Via Benzinga

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗

November 18, 2022

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.

Via Benzinga

Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder ↗

November 17, 2022

Via Benzinga

Editas Medicine: Q2 Earnings Insights ↗

August 03, 2022

Editas Medicine (NASDAQ:EDIT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 17, 2022

Via Benzinga

S&P 500 Down 1%; Crude Oil Drops Sharply ↗

November 17, 2022

U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday.

Via Benzinga

BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗

November 17, 2022

U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 17, 2022

Via Benzinga

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

November 17, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

What 5 Analyst Ratings Have To Say About Editas Medicine ↗

November 03, 2022

Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

November 02, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

October 26, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

October 13, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 ↗

September 29, 2022

Upgrades

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

3 Biotech Stocks Gaining Momentum

September 12, 2022

The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.

Via MarketBeat

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

July 27, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

July 26, 2022

From Editas Medicine, Inc.

Via GlobeNewswire

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.